{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000037","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-07-16T20:06:13+00:00","discovered_at":"2026-07-16T20:07:00.304056+00:00","generated_at":"2026-07-16T20:07:05.325513+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inhibrx expands credit facility to $500M with Oxford Finance, receives $100M upfront","bullets":["Total facility expanded to $500M; $100M funded immediately as Term C Loan, up to $225M more at lenders' discretion.","Prior to amendment, $175M had been drawn under the original facility.","Issued warrants to purchase 21,457 shares at $93.21 per share in connection with Term C Loan.","Proceeds to support clinical development of ozekibart (INBRX-109) and INBRX-106."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000037","json":"https://secwatch.observer/filing/0002007919-26-000037.json","markdown":"https://secwatch.observer/filing/0002007919-26-000037.md","text":"https://secwatch.observer/filing/0002007919-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/0002007919-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/inhibrx-20260715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T20:07:05.325513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}